Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $191.77

Ascendis Pharma A/S (NASDAQ:ASND) has earned an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $191.77.

A number of brokerages recently weighed in on ASND. TD Cowen lowered their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. The Goldman Sachs Group boosted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Wells Fargo & Company boosted their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Finally, Citigroup raised their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th.

Ascendis Pharma A/S Stock Up 2.7 %

Shares of NASDAQ:ASND opened at $140.30 on Friday. The firm has a market cap of $8.51 billion, a P/E ratio of -17.36 and a beta of 0.67. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The company’s 50-day moving average price is $129.27 and its two-hundred day moving average price is $132.75.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $30,000. Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $60,000. Signaturefd LLC lifted its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Searle & CO. bought a new stake in Ascendis Pharma A/S in the 2nd quarter valued at $205,000. Finally, Rhumbline Advisers boosted its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.